Melvin Capital Management’s Labcorp LH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-772,694
Closed -$204M – 24
2022
Q1
$204M Sell
772,694
-1,203,306
-61% -$329M 2.07% 26
2021
Q4
$621M Buy
1,976,000
+76,000
+4% +$21.9M 3.03% 6
2021
Q3
$535M Sell
1,900,000
-50,000
-3% -$14.7M 2.72% 7
2021
Q2
$538M Buy
1,950,000
+450,000
+30% +$119M 3.09% 4
2021
Q1
$383M Buy
1,500,000
+635,000
+73% +$148M 2.19% 9
2020
Q4
$176M Sell
865,000
-763,006
-47% -$153M 0.74% 43
2020
Q3
$307M Buy
1,628,006
+628,006
+63% +$116M 1.53% 23
2020
Q2
$166M Sell
1,000,000
-1,570,950
-61% -$253M 0.98% 29
2020
Q1
$325M Buy
2,570,950
+1,095,317
+74% +$184M 2.59% 11
2019
Q4
$250M Sell
1,475,633
-544,844
-27% -$91.6M 2.05% 19
2019
Q3
$339M Buy
2,020,477
+1,245,477
+161% +$212M 2.75% 10
2019
Q2
$134M Buy
+775,000
New +$126M 1.37% 23

Other funds holding LH

Melvin Capital Management's LH Position: Q2 2022 in Review

Melvin Capital Management sold out of Labcorp (LH) in Q2 2022, closing a stake of 772,694 shares — an estimated $204M sold.

Melvin Capital Management first reported a position in LH in Q2 2019 and held it in 12 quarters. The position peaked at $621M in Q4 2021. 964 funds tracked by Wall St. Rank hold LH as of Q2 2022.

  • Melvin Capital Management reported no remaining Labcorp position as of Q2 2022 after selling out during the quarter.
  • Melvin Capital Management sold 772,694 Labcorp shares in Q2 2022, an estimated $204M.
  • Melvin Capital Management first reported a position in Labcorp in Q2 2019 and held it in 12 quarters.
  • Melvin Capital Management's Labcorp position peaked at $621M in Q4 2021.
  • 964 funds tracked by Wall St. Rank held Labcorp as of Q2 2022.

Based on Melvin Capital Management's 13F filing for Q2 2022.